Blog Archives
Alzheimer’s disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease
Wang Z, Lewis V, Stehmann C, Verghese S, Senesi M, McGlade A, Ellett L, Doecke JD, Eratne D, Velakoulis D, Masters CL, Collins SJ, Li Q-X.
The Association Between Alzheimer’s Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults
Pedrini S, Chatterjee P, Nakamura A, Tegg M, Hone E, Rainey-Smith S, Rowe CC, Doré V, Villemagne VL, Ames D, Kaneko N, Gardener S, Taddei K, Fernando B, Martins I, Bharadwaj P, Sohrabi HR, Masters CL, Brown B, Martins RN, and the AIBL Research Group.
Sex-dependent cholinergic effects on amyloid pathology: A translational study
German-Castelan L, Shanks HRC, Gros R, Saito T, Saido TC, Saksida LM, Bussey TJ, Prado MAM, Schmitz TW, Prado VF; Australian Imaging Biomarkers and Lifestyle flagship study of ageing.
CenTauR: Toward a universal scale and masks for standardizing tau imaging studies
Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, Bourgeat P, Lopresti B, Huang K, Krishnadas N, Fripp J, Takado Y, Gogola A, Minhas D, Weimer R, Higuchi M, Stephens A, Hansson O, Doré V ; Alzheimer’s Disease Neuroimaging Initiative and the AIBL research group (2023).
Plasma Amyloid-beta Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, Kato T, Rowe CC, Arahata Y, Iwamoto S, Ito K, Tanaka K, Yanagisawa K, Masters CL, Nakamura A (2020).
Total Aβ(42)/Aβ(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke JD, Pérez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, Pesini P, Sarasa M (2020).
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
Burnham SC, Fandos N, Fowler C, Pérez-Grijalba V, Dore V, Doecke JD, Shishegar R, Cox T, Fripp J, Rowe C, Sarasa M, Masters CL, Pesini P, Villemagne VL (2020).
Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease
Lim WLF, Huynh K, Chatterjee P, Martins I, Jayawardana KS, Giles C, Mellett NA, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Drew BG, Masters CL, Meikle PJ, Martins RN (2020).
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease
Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, Bourgeat P, Li QX, Collins S, Bush AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow K, Zetterberg H, Martins RN (2020).
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith SR, Martins RN, Masters CL, AIBL (2020).